Peptide · Agonist of natriuretic peptide receptor-B (NPR2) · developed by Biomarin Pharm
Vosoritide is a modified recombinant human C-type natriuretic peptide analog that binds natriuretic peptide receptor-B, counteracting FGFR3 downstream signaling through the MAPK pathway and promoting endochondral bone growth. It is studied in achondroplasia, idiopathic short stature and hypochondroplasia.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 25, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07441876 | Phase 2/3 | Achondroplasia | Recruiting | BMRN |
| NCT06455059 | Phase 3 | Hypochondroplasia | Completed | BMRN |
| NCT03424018 | Phase 3 | Achondroplasia | Active not recruiting | BMRN |
| NCT06382155 | Phase 2 | Idiopathic Short Stature | Recruiting | BMRN |
| NCT03989947 | Phase 2 | Achondroplasia | Active not recruiting | BMRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AchondroplasiaHypochondroplasiaIdiopathic Short Stature
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.
See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMRN catalysts and pipeline →